Evidence map›Paper›PMID 42729944›Full record

ReviewBrain communications2026

Developmental brain programmes and biomarker activation in Alzheimer's disease.

Lorenzo Pini, Monica Margoni, Massimo Filippi, Bruno Pietro Imbimbo

Abstract readReview
In one paragraph

Review in Brain communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lorenzo PiniDepartment of Neuroscience, University of Padova, Padova 35122, Italy.
Monica MargoniNeurology Unit, IRCCS San Raffaele Scientific Institute, Milan 20132, Italy.
Massimo FilippiNeuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan 20132, Italy.ORCID https://orcid.org/0000-0002-5485-0479
Bruno Pietro ImbimboDepartment of Research and Development, Chiesi Farmaceutici, Parma 43122, Italy.ORCID https://orcid.org/0000-0002-0327-7262

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent studies show that serum glial fibrillary acidic protein (GFAP) is highest in healthy infancy and early childhood and then declines steadily with age, while plasma tau protein phosphorylated at position 217 is strikingly elevated in healthy newborns and can exceed values observed in Alzheimer's disease (AD). Additional evidence indicates that soluble phosphorylated tau forms are not specific to AD, as increased tau protein phosphorylated-217 has been reported in

Indexed as

biomarker biologyGFAPneurodevelopmentp-tau217sTREM2

Identifiers

PMID42729944
PMCPMC13563286

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.